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Human polyoma JC virus (JCV) is a largely brain cell-specific virus that is associated with AIDS. The neurotropism involves
the various transcription factors interacting with their cognate sequences in the JCV early (JCVE) and late (JCVL) promoters-
enhancer, but the mechanism is unclear. The JCV tandem AGGGA pentanucleotide double repeat element (Pnt2) and the
abutting NF1 site form a composite Pnt2 (cPnt2). Here, we studied the roles of both sites of cPnt2 in the expression of
JCVE and JCVL . JCVE activity was progressively increased in U-87 MG human glioblastoma cells following the site-specific
mutation of Pnt2 in one and both 98-bp repeats. In contrast, the activity for JCVL was progressively reduced by mutating
single and double Pnt2s. However, JCVE activity was unaffected by mutating both Pnt2s when both NF1 sites of cPnt2 were
mutated. The activity of JCVL was also unaffected by double Pnt2 mutations after the NF1 sites were mutated. Differentiating
P19 glial cells showed similar results. Next, Pnt2-interacting proteins were examined by two in vitro assays with a Pnt2
oligonucleotide. Mobility shift assays showed one Pnt2–protein complex for U-87 MG cell extracts and two for P19 glial
cell extracts. However, similar results were obtained for glial, muscle, and undifferentiated P19 cells. In UV cross-linking
assays, two Pnt2-binding proteins (Pnt2BPs) were detected. The results suggested that the effects on JCVE and JCVL
expression of Pnt2BP and NF1 via cPnt2 are dual and require a glial cell-specific NF1 function. q 1997 Academic Press
INTRODUCTION Herein, Pnt2-interacting protein is referred to as Pnt2-
binding protein (Pnt2BP).
Human polyoma JC virus (JCV) is a neurotropic AIDS-
Pnt2BP is also involved in the large tumor antigen (T-associated virus that is highly brain cell-specific for multi-
Ag)-mediated replication of JCV DNA (Chang et al., 1994).plication and gene expression (reviewed by Frisque and
Therefore, the binding of Pnt2BP might contribute to theWhite, 1992). The glial cell specificity of expression was
replication of JCV mediated by T-Ag (Chang et al., 1994).attributed mainly to various transcription factors inter-
Pnt2 is not present near the SV40 origin of replication,acting with the specific cis-acting binding sequences of
but is present seven times in the regulatory region of JCV.the JCV early (JCVE) and late (JCVL) promoters-enhancer
Further, the presence of Pnt2 stimulated the replication of(for review see Raj and Khalili, 1995). Gene expression
JCV, but not SV40 (Lynch and Frisque, 1990). The overallby JCVE and JCVL is positively and negatively regulated
results suggested that Pnt2 is involved in the glial cellby a number of transcription factors. Studies showed
specificity of JCV via the regulation of replication, as wellthat the tandem AGGGA pentanucleotide double repeat
as transcription, of JCV.element (which we call Pnt2) present in both 98-bp re-
Pnt2 is abutted by a nuclear factor 1 (NF1) site (Raj andpeats of the JCV regulatory region were used to down-
Khalili, 1995). Generally, NF1 is a family of transcriptionregulate JCVL activity. Further, several 50- to 120-kDa
factors that is present in different cells. NF1 has alsoproteins called various names were identified that inter-
become increasingly characterized for its transcriptionalacted with the AGGGA pentanucleotide repeat element
role in brain cell specificity, especially in glial cells (Ta-(see Raj and Khalili, 1995 for review). A 56- to 60-kDa
mura et al., 1989; Amemiya et al., 1992; Kumar et al.,protein interacted only in glial cell extracts and thus may
1993; Kumar et al., 1996a). Since the cell-specific geneact as the represser of JCVL activity (Tada et al., 1991).
expression and replication of JCV involve NF1 (Sock et
al., 1993) and Pnt2 (Chang et al., 1994), further character-1 Present address: Toronto General Hospital, Toronto, Ontario, Can-
ization of the combined functions is important. Here, weada M5G 2C4.
report the identification of dual effects of Pnt2: down-2 Present address: Howard Hughes Medical Institute, MSRB II, Uni-
versity of Michigan, Ann Arbor, MI 48109-0650. regulation of the expression of JCVE and up-regulation of
3 Mary Pater passed away on November 2, 1994. JCVL in U-87 MG (U-87) and P19 embryonal carcinoma4 To whom correspondence and reprint requests should be ad- cells. Furthermore, the dual function of Pnt2 was depen-dressed at Basic Medical Sciences, Faculty of Medicine, Memorial
dent on the integrity of the NF1 sites of the compositeUniversity of Newfoundland, St. John’s, Newfoundland, Canada A1B
3V6. Fax: 709-737-7010. E-mail: apater@morgan.ucs.mun.ca. Pnt2–NF1 site (cPnt2).
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MATERIALS AND METHODS
Plasmids and mutagenesis
The JCV promoter-enhancer region nt 270–5112 PvuII–
HindIII fragment was used as the template for site-di-
rected mutagenesis. Mutations were introduced into
Pnt2 in either the 98-bp repeat B (mpB), or A and B
repeats (mpAB). Both NF1 repeats were mutated and the
plasmid was called pJCVEcatII.III previously (Kumar et
al., 1993) and was called mnAB here. The plasmid with
all four sites mutated (mpnAB) was made, using mnAB
as template (Fig. 1). The Muta-Gene R Phagemid In Vitro
Mutagenesis kit (Bio-Rad) was used. The 5*-GGCCAG-
CCATTAGATCTGTTTTTTTT-3* 26-mer was the mutation
oligonucleotide primer for Pnt2. Wild type (ABWT) was
prepared and described as pJCVEcat and pJCVLcat earlier
(Nakshatri et al., 1990); mutated JCV promoters-enhancer
were similarly inserted into the HindIII site of the pSV0cat
chloramphenicol acetyltransferase (CAT) reporter plas-
mid in the early and late orientations. The names of the
plasmids in both orientations were the same.
Cell culture, DNA transfection, and expression assays
P19 embryonal carcinoma cells and U-87 human gli-
oblastoma cells were cultured in a-Dulbecco’s modified
Eagles’ medium. P19 cells were undifferentiated, were
treated with 1% dimethyl sulfoxide to differentiate into
mostly skeletal and cardiac muscle cells or were differ-
entiated into a mixture of neuronal, glial, and other cells
FIG. 1. Effect of Pnt2 and NF1 sites on JCVE and JCVL in vivo expres-with 300 nM retinoic acid (RA), as described previously
sion. On top is shown a diagram of wild-type JCV sequences. The 98-(Rudnicki and McBurney, 1987). The cells are called glial
bp A and B repeats of JCV are shown as large boxes containing smallcells, since the majority of RA cells expressing trans-
boxes for the indicated binding sites, which are described in the text.
fected DNA are glial (Kumar et al., 1996b; Reddy et al., Early and late directions of gene expression are indicated. Below the
1996). Cells were transfected, as described previously diagram are shown the expression plasmids that were assayed in U-
87 and P19 cells by transient transfection, as described in the text,(Nakshatri et al., 1990; Kumar et al., 1993). CAT transient
and the JCV sequences which the plasmids contain. Capital letters andtranscriptional expression was assayed and normalized
hyphens represent wild-type (ABWT) nucleotides and lower case lettersfor transfection and transcription efficiencies with b-ga-
represent mutated nucleotide. Wild-type Pnt2 sequences are under-
lactosidase assays, as described previously (Gorman et lined and wild-type NF1 sites are overlined. On the bottom are the
al., 1982; Kumar et al., 1993). results of CAT assays for the indicated cells for the activity (percentage
conversion) for the pJCVLcat and pJCVEcat plasmids with the same
DNA binding assays names. The plasmid names are indicated below the charts and are
described above the CAT assay results. The results are the averageNuclear extracts of undifferentiated P19 cells, P19 glial //0 the standard deviation for three independent experiments.
cells, P19 muscle cells, and U-87 cells were prepared,
as described earlier (Hennighausen and Lubon 1987).
The Pnt2 5*-GATCAGGGAAGGGA-3* 14-mer double- ing site, cGRE, in epitheliotropic viral expression (Mittal
stranded oligonucleotide was the probe and homologous et al., 1994). Neurotropic JCV has an analogous cPnt2
wild-type (w) competitor. The mutated (m) competitor was containing adjacent Pnt2 and NF1 sites. Also, JCVE ex-
the 5*-GATCACAGATCTAA-3* 13-mer. Electrophoretic pression is cell-specific. Therefore, we first examined the
mobility shift assays (EMSAs) were described previously function of the Pnt2 cis-element in the glial cell system
(Chodosh et al., 1988). UV cross-linking assays also were for the regulation of the activity of JCVL and JCVE . One
described previously (Chodosh et al., 1986). or both Pnt2s were mutated by site-directed mutagenesis
(Fig. 1). The plasmids were then assayed in U-87 gli-RESULTS
oblastoma cells and RA-differentiated P19 glial cells to
Dual effect of Pnt2 on JCVE and JCVL activity test the role of the JCV Pnt2 in in vivo expression.
The activity of JCVL was considerable from expressionWe previously found an important role of the combined
functions of both HPV16 sites of the composite GRE bind- plasmid with intact A and B wild-type 98-bp repeats
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(ABWT) in U-87 cells and P19 glial cells (Fig. 1). The In vitro interaction of JCV Pnt2 with proteins from
different cell typesmutation of Pnt2 in the 98-bp repeat B (mpB) reduced
JCVL activity 40% in U-87 cells and 26% in P19 glial cells.
In vitro interaction of a glial cell-specific protein withWhen both repeat Pnt2s were mutated (mpAB), JCVL ac-
the JCV NF1 sites in P19 cells was shown previouslytivity was reduced 65% in U-87 cells and 50% in P19 glial
(Nakshatri et al., 1990; Amemiya et al., 1992; Kumar etcells. In contrast, JCVE expression was increased 2.5-
al., 1993). Other reports showed that 53-, 56-, 60-, or 70-,fold in U-87 cells and 2-fold in P19 glial cells when one
80-kDa and other proteins interacted with the AGGGAPnt2 repeat was mutated in mpB (Fig. 1). The double
double repeat element to regulate the expression of JCVEmutation of Pnt2s in mpAB increased the JCVE activity 7-
and JCVL in various cell systems (Kumar et al., 1994;fold in U-87 cells and 2.5-fold in P19 glial cells (Fig. 1).
Sharma and Kumar, 1991; Tada et al., 1991; reviewed inThese results indicated that both Pnt2s are indepen-
Raj and Khalili, 1995). The results in Fig. 1 suggested thedently, additively, and dually important in regulating JCVL
interaction of a protein(s) with Pnt2. Therefore, we testedand JCVE expression in glial cells, positively regulating
the possibility of a protein(s) binding in the nuclear ex-JCVL and negatively regulating JCVE .
tracts of the differentiating P19 cells and U-87 glioblas-
Role of NF1 sites in cPnt2 toma cells. First, we evaluated the binding of native pro-
teins. Two main complexes with the Pnt2 double-To examine the effects of only NF1 sites in cPnt2,
stranded oligonucleotide were observed with the extractwhich consists of an adjacent NF1 site and Pnt2, the
of RA P19 glial cells in electrophoretic mobility shiftexpression of the constructs with both mutated NF1 sites
assays, EMSAs (Fig. 2A, RA, 0lane). The specificity of(mnAB) was assayed. The results showed that JCVL activ-
this interaction was examined with competition experi-ity in U-87 cells was substantially reduced when both
ments. The Pnt2 double-stranded oligonucleotide wild-NF1 sites were mutated in mnAB (Fig. 1). Similarly, the
type competitor eliminated EMSA binding (/w lane),activity of JCVE was reduced by the mutation of NF1 sites.
while the mutated competitor had no effect (/m lanes).The NF1 results for JCVL and JCVE in P19 glial cells were
EMSAs were also examined using U-87 cell extract. Onlyalso examined and were consistent with the U-87 results
one complex was observed and the binding was againand previous results (Fig. 1; Kumar et al., 1993, 1996a).
specific to the wild-type oligonucleotide (Fig. 2B).Therefore, the effects of mutating only Pnt2s and only
Others reported the interaction of a 70- to 80-kDa pro-NF1 sites in both glial cell types were different, with
tein in nuclear extracts of nonglial cells with Pnt2 (Kumarpositive and negative effects for Pnt2s on JCVL and JCVE
et al., 1994). Thus, EMSAs were also done using nuclearactivities, respectively. In contrast, the effects were posi-
extracts from nonglial cells, P19 undifferentiated (UD)tive for the NF1 sites for both JCV promoters (Fig. 1).
cells (Fig. 2A), and DMSO-differentiated muscle cellsThe JCV Pnt2s of the 98-bp repeats abut the NF1 sites
(Fig. 2C). Two main complexes were found. Finding simi-(Fig. 1). Thus they form a cPnt2, and such composite
lar mobilities of the Pnt2–Pnt2BP complexes in undiffer-binding sites are implicated in complex regulation of
entiated cell and RA glial cells suggests that the proteinsgene expression. As both Pnt2s and NF1 sites were
in both cell types were the same. Therefore, the proteinshown to affect JCV activity substantially (Fig. 1), we ex-
binding to Pnt2 was not glial cell-specific, unlike thoseamined the possible functional interaction between Pnt2
binding to the NF1 sites in the JCV cPnt2 binding siteand NF1 in the adjacent sites in cPnt2. Therefore, the
(Fig. 2; Nakshatri et al., 1990; Kumar et al., 1993).JCVL and JCVE expression plasmids containing all four
mutated Pnt2s and NF1 sites (mpnAB) were assayed for
the combined in vivo effects on expression of JCVL and Characterization of proteins binding to Pnt2
JCVE in U-87 cells and P19 glial cells (Fig. 1). For JCVL ,
mpnAB had the same activity as both mpAB and mnAB. Various cell systems were used previously and gave
conflicting results for the size and number of Pnt2BPs.Only mpAB was slightly higher for glial cells. Thus, the
results show that the integrity of the NF1 sites is essential Therefore, UV cross-linking assays were used to assess
the size of the Pnt2BP(s) that interacted with JCV (Fig. 3).for the effects of Pnt2. More implication could be drawn
from the results for JCVE . The mutation of all four sites in The same double-stranded oligonucleotide probe that
was used for EMSAs was UV-cross-linked with proteinsmpnAB gave the same activity as that of mnAB containing
mutated NF1 sites alone. Therefore, the substantial re- in the P19 glial cell nuclear extract. The results showed
two Pnt2BPs with apparent molecular weights of 65 andduction in JCVE expression due to the loss of the NF1
site was retained, whereas the 7-fold and 2.5-fold in- 43 kDa. The Pnt2–Pnt2BPs interactions were specific,
as the homologous oligonucleotide efficiently competedcreases due to the loss of Pnt2s required the functional
NF1 sites. Phrased differently, the function of Pnt2 appar- the binding of both complexes, while the competitor con-
taining the mutated Pnt2 did not affect the binding (Fig.ently requires the integrity of NF1 binding sites to repress
JCVE transcriptional activity. The activator function of Pnt2 3). Combined with the JCVL and JCVE expression results
(Fig. 1), the EMSA results (Fig. 2), and the previous data,for JCVL may similarly require NF1 (Fig. 1).
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FIG. 2. Electrophoretic mobility shift assays (EMSAs) for proteins binding with JCV Pnt2 in vitro. Double-stranded oligonucleotides containing
Pnt2 were end-labeled to probe 5 mg protein in nuclear extracts. Labels are: F, free probe without extract; B, binding with extracts; B plus 0, binding
without competitor; B plus /w, as in B plus 0 lane plus 250- to 500-fold excess wild-type homologous competitor; B plus /m, as in B plus 0 lane
plus 250- to 500-fold excess mutated competitor. Arrows indicate the specific DNA–protein complexes. Arrowheads indicate free probe. (A) Binding
assays with P19 RA glial cell nuclear extracts (RA) and P19 undifferentiated cell extracts (UD); (B) Assays with U-87 glioblastoma cell extracts (U87);
(C) Assays with P19 muscle cell nuclear extracts (DM).
the results indicated that the AGGGAAGGGA cis-acting well as positive (Raj and Khalili, 1995). The negative regu-
lation of JCVE was first identified in glial–fibroblast fusionelement, Pnt2, in JCV regulates gene expression.
experiments (Beggs et al., 1988). Subsequently, the cis-
DISCUSSION acting elements were identified in the JCV transcription
regulatory region using JCV–BKV and JCV–SV40 hybridA number of reports have shown that the regulation
viruses (Bollag et al., 1989). Several proteins were shownof gene expression from JCVE and JCVL is negative as
binding to the JCV promoter-enhancer region. These pro-
teins play an important role in JCV expression in glial
cells (Raj and Khalili, 1995). Protein(s) from glial cell ex-
tracts specifically interacts with NF1 binding motifs lo-
cated in the 98-bp repeat regions of JCV (Kumar et al.,
1993; Nakshatri et al., 1990; Amemiya et al., 1989; Khalili
et al., 1988). Earlier, it was reported that a 53-kDa protein
from nonglial HeLa cells interacts with the AGGGA dou-
ble repeat element (Sharma and Kumar, 1991). However,
another study demonstrated that a 56- to 60-kDa protein
in glial cell extracts binds specifically to the AGGGA
double repeat element (Pnt2) and down-regulates the
transcriptional activity of JCVL (Tada et al., 1991). In con-
trast, our studies showed that the AGGGA double repeat
element, Pnt2, down-regulates the expression of JCVE
and up-regulates the activity of JCVL . The implication of
these findings is that the cis-acting Pnt2 might repress
JCVE expression in nonglial and glial cells. However, in
glial cells the repression of JCVE by Pnt2 is overcome by
the strong positive effect of NF1, leading to JCVE expres-
sion. Due to the lack of NF1 in nonglial cells, JCVE is
FIG. 3. UV cross-linking assays to determine size of proteins binding repressed by Pnt2. Thus, glial cell specificity of JCVEto Pnt2 of JCV. The probe used for UV cross-linking was labeled by
results.nick translation. For each assay, 50 mg protein were used. Numbers on
In the present study, since we used the whole pro-the left indicate protein markers in kDa. Other labels are as described in
the legend of Fig. 2. moter-enhancer of JCV, the function of Pnt2 was tested
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in the context of the whole JCV transcriptional control up-regulation of JCVE . In contrast, for the expression of
JCVL , the TATA box plays no major role and interactionregion. This region contains binding sites for factors af-
fecting JCVE and JCVL positively and negatively (Raj and between Pnt2BP and NF1 is required for JCVL function.
Therefore, JCVL activity is reduced when the positive-Khalili, 1995), consistent with our findings. Interactions
between proteins on adjacent sites may confer alternate acting Pnt2 is mutated. The complex regulation by cPnt2
of JCV expression reported here furthers our understand-positive or negative regulation, as observed for YY1’s
effect on HPV18 gene expression (Bauknecht et al., ing of gene expression in glial cells of JCV in particular
and in glial cell transcription control mechanisms in gen-1995). The JCV promoter-enhancer region binding sites
interact with several glial cell-specific and nonspecific eral.
factors. Further, using two glial cell systems, P19 RA-
differentiated cells and U-87 glioblastoma cells, we dem- ACKNOWLEDGMENTS
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